This database contains 15 studies, archived under the term: "Alzheimer's & Dementia: The Journal Of The Alzheimer's Association"
Click here to filter this large number of results.
Alzheimer’s Disease Anti-inflammatory Prevention Trial: design, methods, and baseline results
Background: The Alzheimer’s Disease Anti-inflammatory Prevention Trial (ADAPT) was designed to address whether non-steroidal anti-inflammatory drugs (NSAIDs) can prevent or delay the onset of Alzheimer’s disease (AD).; Methods: ADAPT was a randomized, double-placebo-controlled, multicenter chemoprevention trial conducted at six U.S. dementia research clinics. At entry, participants were required to test “normal” on a battery of […]
Vitamin E and memantine in Alzheimer’s disease: clinical trial methods and baseline data
Dysken, Maurice W.,
Guarino, Peter D.,
Vertrees, Julia E.,
Asthana, Sanjay,
Sano, Mary,
Llorente, Maria,
Pallaki, Muralidhar,
Love, Susan,
Schellenberg, Gerard D.,
McCarten, J. Riley,
Malphurs, Julie,
Prieto, Susana,
Chen, Peijun,
Loreck, David J.,
Carney, Sara,
Trapp, George,
Bakshi, Rajbir S.,
Mintzer, Jacobo E.,
Heidebrink, Judith L.,
Vidal-Cardona, Ana,
Arroyo, Lillian M.,
Cruz, Angel R.,
Kowall, Neil W.,
Chopra, Mohit P.,
Craft, Suzanne,
Thielke, Stephen,
Turvey, Carolyn L.,
Woodman, Catherine,
Monnell, Kimberly A.,
Gordon, Kimberly,
Tomaska, Julie,
Vatassery, Govind
Background: Alzheimer’s disease (AD) has been associated with both oxidative stress and excessive glutamate activity. A clinical trial was designed to compare the effectiveness of (i) alpha-tocopherol, a vitamin E antioxidant; (ii) memantine (Namenda), an N-methyl-D-aspartate antagonist; (iii) their combination; and (iv) placebo in delaying clinical progression in AD.; Methods: The Veterans Affairs Cooperative Studies […]
Assessment of cognition in mild cognitive impairment: a comparative study
Snyder, Peter J.,
Jackson, Colleen E.,
Petersen, Ronald C.,
Khachaturian, Ara S.,
Kaye, Jeffrey,
Albert, Marilyn S.,
Weintraub, Sandra
The demand for rapidly administered, sensitive, and reliable cognitive assessments that are specifically designed for identifying individuals in the earliest stages of cognitive decline (and to measure subtle change over time) has escalated as the emphasis in Alzheimer’s disease clinical research has shifted from clinical diagnosis and treatment toward the goal of developing presymptomatic neuroprotective […]
Efficacy of a medical food in mild Alzheimer’s disease: A randomized, controlled trial
Scheltens, Philip,
Kamphuis, Patrick J. G. H.,
Verhey, Frans R.J.,
Olde Rikkert, Marcel G. M.,
Wurtman, Richard J.,
Wilkinson, David,
Twisk, Jos W.R.,
Kurz, Alexander
Objective: To investigate the effect of a medical food on cognitive function in people with mild Alzheimer’s disease (AD).; Methods: A total of 225 drug-naïve AD patients participated in this randomized, double-blind controlled trial. Patients were randomized to active product, Souvenaid, or a control drink, taken once-daily for 12 weeks. Primary outcome measures were the […]
Impact of molecular imaging on the diagnostic process in a memory clinic
Ossenkoppele, Rik,
Prins, Niels D.,
Pijnenburg, Yolande A.L.,
Lemstra, Afina W.,
van der Flier, Wiesje M.,
Adriaanse, Sofie F.,
Windhorst, Albert D.,
Handels, Ron L.H.,
Wolfs, Claire A.G.,
Aalten, Pauline,
Verhey, Frans R.J.,
Verbeek, Marcel M.,
van Buchem, Mark A.,
Hoekstra, Otto S.,
Lammertsma, Adriaan A.,
Scheltens, Philip,
van Berckel, Bart N.M.
Background: [(11)C]Pittsburgh compound B ([(11)C]PIB) and [(18)F]-2-fluoro-2-deoxy-D-glucose ([(18)F]FDG) PET measure fibrillar amyloid-β load and glucose metabolism, respectively. We evaluated the impact of these tracers on the diagnostic process in a memory clinic population.; Methods: One hundred fifty-four patients underwent paired dynamic [(11)C]PIB and static [(18)F]FDG PET scans shortly after completing a standard dementia screening. Two-year […]